Pure Bioscience Changes Fiscal Year End
Ticker: PURE · Form: 8-K · Filed: Aug 9, 2024 · CIK: 1006028
| Field | Detail |
|---|---|
| Company | Pure Bioscience, Inc. (PURE) |
| Form Type | 8-K |
| Filed Date | Aug 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: fiscal-year-change, financial-reporting
TL;DR
PURE changed its fiscal year end to July 31. New financials coming.
AI Summary
Pure Bioscience, Inc. filed an 8-K on August 9, 2024, reporting a change in its fiscal year end to July 31, with the most recent fiscal year ending on July 31, 2024. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal business address is in El Cajon, California.
Why It Matters
This change in fiscal year end can affect the timing of financial reporting and investor analysis. It may also indicate internal strategic shifts within the company.
Risk Assessment
Risk Level: low — This filing is primarily administrative, reporting a change in fiscal year end and including standard financial statements and exhibits, with no immediate negative or positive financial implications.
Key Players & Entities
- PURE BIOSCIENCE, INC. (company) — Registrant
- August 5, 2024 (date) — Earliest event reported
- August 9, 2024 (date) — Filing date
- July 31 (date) — New fiscal year end
- Delaware (jurisdiction) — State of incorporation
- 771 Jamacha Rd. #512 El Cajon , California (address) — Business address
FAQ
What is the new fiscal year end for Pure Bioscience, Inc.?
The new fiscal year end for Pure Bioscience, Inc. is July 31.
When was this 8-K filing submitted?
This 8-K filing was submitted on August 9, 2024.
What is the state of incorporation for Pure Bioscience, Inc.?
Pure Bioscience, Inc. is incorporated in Delaware.
What is the principal business address of the company?
The principal business address is 771 Jamacha Rd. #512, El Cajon, California.
What items are being reported in this 8-K filing?
This 8-K filing reports amendments to articles of incorporation or bylaws, change in fiscal year, and financial statements and exhibits.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-08-09 16:05:32
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex3-1.htm (EX-3.1) — 2KB
- ex3-1_001.jpg (GRAPHIC) — 900KB
- ex3-1_002.jpg (GRAPHIC) — 265KB
- 0001493152-24-030966.txt ( ) — 1544KB
- pure-20240805.xsd (EX-101.SCH) — 3KB
- pure-20240805_lab.xml (EX-101.LAB) — 33KB
- pure-20240805_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PURE BIOSCIENCE, INC. Dated: August 8, 2024 By: /s/ Robert Bartlett Robert Bartlett President and Chief Executive Officer (Principal Executive Officer)